Randa Bascharon: When to Consider Wharton’s Jelly in Tendon, Ligament, and Joint Conditions
Randa Bascharon, Founder, President and Orthopedic Surgeon at Sports Performance Institute of Las Vegas, shared a post on LinkedIn:
“Wharton’s Jelly is increasingly discussed in orthopedic and sports medicine settings, particularly among active patients looking for non-surgical options.
Wharton’s Jelly is derived from donated umbilical cord tissue and contains growth factors and signaling proteins that may support the body’s healing environment.
In clinical practice, it is considered in select cases involving tendon injuries, ligament issues, or certain joint conditions.
A few practical points are important:
- First, it is not the same as a steroid injection.
- Second, it is different from platelet-rich plasma.
- Third, it is not a universal substitute for surgery.
Candidacy varies.
The decision to consider a biologic injection depends on the diagnosis, severity of tissue damage, functional goals, prior treatments, and imaging findings.
Thoughtful patient selection matters.
For athletes and active adults, the real question is not whether a treatment is popular.
It is whether it aligns with the biology of their specific injury and their long-term performance goals.
If you are seeing more patients ask about biologics, how are you approaching education and expectation setting in your practice?
Educational only.
A diagnosis and treatment plan require an in-person evaluation.”

See more in the gallery.
Stay updated with Hemostasis Today.
-
Nov 18, 2026, 14:49Estetrol-Based Contraception in PCOS and Its Effects on Coagulation – RPTH Journal
-
Nov 18, 2026, 14:41Factor V Deficiency: Diagnostic Challenges and the Role of Combined Factor V and VIII Deficiency
-
Nov 18, 2026, 14:29Maxime Dely: When Patient Encounters Become Life Lessons
-
Nov 18, 2026, 14:23Basanta Khatiwada: Advancing Haematology Through Research and Innovation at HAEMATOCON 2026
-
Nov 18, 2026, 14:13Alvin Katumba: Sickle Cell Disease Research Recognised With a 2026 ASH Abstract Achievement Award
-
Nov 18, 2026, 13:34Vincenzo De Angelis: Strengthening Plasma Management and Quality Control in Eastern Europe
-
Nov 18, 2026, 13:34Standardizing Bleeding Outcome Assessment in Hemophilia Clinical Trials – JTH
-
Nov 18, 2026, 13:34Nicolas Gendron: Towards Sustainable Anticoagulation
-
Nov 18, 2026, 13:33Breaking the Silence on Women and Girls with Bleeding Disorders – EHC